

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. completed surgery to remove a breast tumor and there isn't any evidence of remaining tumor. 2. Early stage (T1) tumor without lymph node involvement and a Oncotype DX Recurrence Score of less than or equal to 18 3. ER and/or PgR positive and HER2 negative tumor

Exclusion Criteria:

1. tumor size larger than T1 2. surgical procedure was a mastectomy 3. any treatment with radiation therapy, chemotherapy, biotherapy, and/or endocrine therapy given for the currently diagnosed breast cancer prior to study entry 4. Women who are pregnant or breast feeding

Conditions & Interventions

Interventions:

Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Conditions:

Cancer

Keywords:

Breast Cancer, Breast Cancer, Radiation, Stage 1 breast cancer. Hormone positive breast cancer

More Information

Description: We are comparing treatment of early stage, hormone positive breast cancer with and without radiation therapy. One group will receive radiation therapy with endocrine therapy and the other group will receive endocrine therapy alone. We want to find out if there is any difference in how often breast cancer recurs in the same breast.

Study Contact: Kristen Nelson - knelso65@fairview.org

Principal Investigator: Jocelin Huang

IRB

Number: MMCORC044

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.